Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preventing systemic embolism in patients with abnormal ventricular function

G E Raskob1, P C Comp

  • 1University of Oklahoma Health Sciences Center, Oklahoma City.

Cardiology Clinics
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progression of an untreated pseudotumor.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Thrombosis: a major contributor to global disease burden.

Arteriosclerosis, thrombosis, and vascular biology·2014
Same author

Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.

The Journal of bone and joint surgery. British volume·2012
Same journal

At the Edge of the Possible: A New Standard for Cardiovascular Critical Care.

Cardiology clinics·2026
Same journal

End-of-Life Care in the Cardiovascular Intensive Care Unit.

Cardiology clinics·2026
Same journal

Strategies to Reduce Failure to Rescue after Cardiac Surgery.

Cardiology clinics·2026
Same journal

Embracing Enhanced Recovery After Cardiac Surgery Program.

Cardiology clinics·2026
Same journal

Post-Heart Transplantation Intensive Care Unit Recovery: A Phase-Based Approach.

Cardiology clinics·2026
Same journal

A Practical Guide to Intensive Care Unit Management after Left Ventricular Assist Device Implantation.

Cardiology clinics·2026
See all related articles

Aggressive anticoagulant therapy is recommended for acute myocardial infarction patients at high risk of systemic embolism. Antithrombotic treatment may be prudent for other high-risk cardiac conditions due to severe consequences and improved safety.

Area of Science:

  • Cardiology
  • Thrombosis
  • Clinical Trials

Background:

  • Systemic embolism poses severe risks, particularly in acute myocardial infarction (AMI) patients.
  • High-risk groups include those with anterior transmural infarction, left ventricular aneurysm, dilated cardiomyopathy, and cardiac tumors.
  • Lack of definitive trials complicates antithrombotic therapy recommendations for some patient groups.

Purpose of the Study:

  • To evaluate the efficacy of anticoagulant therapy in preventing systemic embolism in high-risk AMI patients.
  • To discuss the potential benefits of antithrombotic therapy in other patient populations at risk for systemic embolism.

Main Methods:

  • Review of clinical trial results supporting anticoagulant use in high-risk AMI.
  • Discussion of evidence and rationale for antithrombotic therapy in other cardiac conditions.

Related Experiment Videos

Main Results:

  • Clinical trials support aggressive anticoagulant therapy for preventing systemic embolism in high-risk AMI patients.
  • Antithrombotic therapy effectiveness is documented in other high-risk patient cohorts.
  • Recent advancements have improved the safety of long-term anticoagulant treatment.

Conclusions:

  • Aggressive anticoagulant therapy is supported for high-risk AMI patients to prevent systemic embolism.
  • Antithrombotic treatment may be considered for patients with chronic left ventricular aneurysm, dilated cardiomyopathy, and cardiac tumors, despite incomplete trial data.
  • The potential benefits of antithrombotic therapy warrant its use unless contraindicated, given the severe consequences of embolism.